Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 4
Submit an article Journal homepage
464
Views
14
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia

Nicholas J. ShortDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Hagop KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Farhad RavandiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Xuelin HuangDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Lianchun XiaoDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
William PlunkettDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Varsha GandhiDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Koji SasakiDivision of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Naveen PemmarajuDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Naval G. DaverDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Gautam BorthakurDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ORCID Iconhttp://orcid.org/0000-0001-7679-6453View further author information
ORCID Icon,
Nitin JainDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Marina KonoplevaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Zeev EstrovDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Tapan M. KadiaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
William G. WierdaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Courtney D. DiNardoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Mark BrandtDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Susan M. O’BrienDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Jorge E. CortesDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
&
Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ;Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA, USACorrespondence[email protected]
View further author information
 show all
Pages 813-820 | Received 15 May 2017, Accepted 25 Jun 2017, Published online: 18 Jul 2017

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.